Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma

Jakobsen Falk, IngridLinköpings universitet,Klinisk farmakologi,Hälsouniversitetet (författare)

Objective: Cyclophosphamide is a conventional pro-drug used in Multiple Myeloma (MM) and other malignancies. The highly polymorphic CYP2B6 is suggested as a major contributor in cyclophosphamide bioactivation, and GST en-zymes are involved in detoxification. Polymorphisms of these enzymes may affect enzyme expression and function as well as treatment outcome. The aim of this study was to investigate the impact of the CYP2B6 SNPs G516T, A785G and C1459T, GSTP1 SNP Ile105Val, and GSTM1 and GSTT1 null variants, on the outcome for cyclophosphamide treated MM patients, in order to find markers of value for individualised therapy. Methods: We used allele specific PCR and Pyrosequencing to investigate the impact of CYP2B6 SNPs G516T, A785G and C1459T, GSTP1 Ile105Val, and GSTM1 and GSTT1 variants, on the outcome for 26 cyclophosphamide treated multiple myeloma patients. Results and Major Conclusion: The CYP2B6 785G carriers had significantly shorter progression free survival (p = 0.048*) and overall survival (p = 0.037*) with 785G/G patients having the worst outcome compared to patients carrying the wild type. A shorter progression free survival was also indicated in patients carrying both CYP2B6 516T & 785G (p = 0.068). These results indicate a predictive role of CYP2B6 SNPs, particularly A785G, in cyclophosphamide treatment.

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
Multiple Myeloma; Cyclophosphamide; CYP2B6; Glutathion-S-Transferases (GST); Single Nucleotide Polymorphisms; Pharmacogenetics; Pyrosequencing

Khan, Muhammad SulemanCOMSATS Institute of Information Technology, Abbottabad, Pakistan (författare)
Thunell, LenaLinköpings universitet,Cellbiologi,Hälsouniversitetet(Swepub:liu)lenek59 (författare)
Nahi, HarethKarolinska University Hospital and Karolinska Institutet, Huddinge, Sweden (författare)
Green, HenrikLinköpings universitet,Klinisk farmakologi,Hälsouniversitetet(Swepub:liu)hengr89 (författare)
Linköpings universitetKlinisk farmakologi (creator_code:org_t)

Ingår i:Journal of Cancer Therapy: Scientific Research Publishing3:1, s. 20-272151-19342151-1942

Av författaren/redakt...: Jakobsen Falk, I ...; Khan, Muhammad S ...; Thunell, Lena; Nahi, Hareth; Green, Henrik

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.